Literature DB >> 9194637

Endocrine abnormalities in ovulatory women with polycystic ovaries on ultrasound.

E Carmina1, L Wong, L Chang, R J Paulson, M V Sauer, F Z Stanczyk, R A Lobo.   

Abstract

Polycystic-appearing ovaries (PAO) on ultrasound have been described in a variety of endocrinopathies and also occur in ovulatory women. By some investigators this is merely referred to as 'PCO' (polycystic ovaries). Although there is controversy in this regard, we do not consider women with PAO/PCO who have no known endocrine disturbance to have polycystic ovary syndrome (PCOS) and therefore prefer not to use the term 'PCO' which is often equated with PCOS. We studied 15 ovulatory women with normal-appearing (NAO) ovaries on ultrasound and 15 matched ovulatory women with PAO/PCO. Compared to ovulatory women, 25 other women were studied who were considered to have PCOS. Of these, 15 were overweight and 10 were of normal weight. All the PCOS women had serum concentrations of luteinizing hormone (LH), testosterone, unbound testosterone, androstenedione and dihydroepiandrosterone sulphate (DHEAS) which were significantly higher (P < 0.01) than values in the normal women, regardless of ovarian morphology. These values were similar in the two groups of ovulatory women with NAO and PAO/PCO. Fasting insulin was elevated in women with PCOS with increased body weight (P < 0.01) and was higher than in ovulatory women with NAO and PAO/PCO and than in women of normal weight with PCOS. Serum insulin-like growth factor (IGF)-I and binding protein (BP)-3 were similar in all groups but serum IGFBP-1 was significantly (P < 0.01) lower in those women with PCOS with increased body weight, compared to all other groups. Compared to values in ovulatory women with NAO, serum IGFBP-1 was also significantly (P < 0.05) lower in women with PAO/PCO and those women with PCOS of normal weight. These lower values were similar in women with PAO/PCO and in normal weight women with PCOS. On an individual basis, an elevation of at least one serum androgen value was found in 33% of women with PAO/PCO. These data confirm that increased body weight accentuates the metabolic alterations in PCOS, but suggest that subtle endocrine disturbances, similar to those that are found in PCOS, may be uncovered in up to a third of ovulatory women with PAO/PCO. It appears that a disturbance of the IGF/IGFBP-1 axis is common and apparently closely associated with alterations in ovarian morphology.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9194637     DOI: 10.1093/humrep/12.5.905

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  12 in total

1.  The clinical ramifications of polycystic ovarian morphology in oocyte donors.

Authors:  M Cho; G Ambartsumyan; H Danzer; K Brennan; M Surrey
Journal:  J Assist Reprod Genet       Date:  2013-01-05       Impact factor: 3.412

2.  Lack of association of INS VNTR polymorphism with polycystic ovary syndrome: a meta-analysis.

Authors:  Liu-ying Song; Jing-rong Luo; Qi-liu Peng; Jian Wang; Li Xie; Yu He; Shan Li; Xue Qin
Journal:  J Assist Reprod Genet       Date:  2014-03-28       Impact factor: 3.412

3.  Brachial artery conductance during reactive hyperemia is increased in women with polycystic ovary syndrome.

Authors:  Nazia Raja-Khan; Showieb A Shuja; Allen R Kunselman; Cynthia S Hogeman; Laurence M Demers; Carol L Gnatuk; Richard S Legro
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2010-11-26       Impact factor: 2.435

4.  The polycystic ovary post-rotterdam: a common, age-dependent finding in ovulatory women without metabolic significance.

Authors:  Erica B Johnstone; Mitchell P Rosen; Rebecca Neril; Deborah Trevithick; Barbara Sternfeld; Rosemary Murphy; Carolyne Addauan-Andersen; Daniel McConnell; Renee Reijo Pera; Marcelle I Cedars
Journal:  J Clin Endocrinol Metab       Date:  2010-08-18       Impact factor: 5.958

5.  Prevalence of Polycystic Ovary Syndrome Phenotypes Using Updated Criteria for Polycystic Ovarian Morphology: An Assessment of Over 100 Consecutive Women Self-reporting Features of Polycystic Ovary Syndrome.

Authors:  Nina M Clark; Amanda J Podolski; Eric D Brooks; Donna R Chizen; Roger A Pierson; Denis C Lehotay; Marla E Lujan
Journal:  Reprod Sci       Date:  2014-02-11       Impact factor: 3.060

Review 6.  Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications.

Authors:  Evanthia Diamanti-Kandarakis; Andrea Dunaif
Journal:  Endocr Rev       Date:  2012-10-12       Impact factor: 19.871

7.  Relationship between 17-hydroxyprogesterone responses to human chorionic gonadotropin and markers of ovarian follicle morphology in women with polycystic ovary syndrome.

Authors:  Kevin H Maas; Sandy S Chuan; Heidi Cook-Andersen; H Irene Su; A Duleba; R Jeffrey Chang
Journal:  J Clin Endocrinol Metab       Date:  2015-01       Impact factor: 5.958

8.  The pathogenetic enigma of polycystic ovary syndrome.

Authors:  S Speca; C Napolitano; G Tagliaferri
Journal:  J Ultrasound       Date:  2007-10-22

Review 9.  Polycystic Ovarian Syndrome: Is It Time to Rename PCOS to HA-PODS?

Authors:  Suvarna Satish Khadilkar
Journal:  J Obstet Gynaecol India       Date:  2016-03-11

10.  Does metformin affect ovarian morphology in patients with polycystic ovary syndrome? A retrospective cross-sectional preliminary analysis.

Authors:  Angela Falbo; Francesco Orio; Roberta Venturella; Erika Rania; Caterina Materazzo; Achille Tolino; Fulvio Zullo; Stefano Palomba
Journal:  J Ovarian Res       Date:  2009-05-31       Impact factor: 4.234

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.